CAR-T Meeting 2023 | Novel third-generation TLR2 co-stimulatory CAR-T cells for B-cell malignancies
In this video, Yasmin Nouri, BSc, MSc, Malaghan Institute of Medical Research, Wellington, New Zealand, shares some insights into the development of a novel third-generation TLR2 co-stimulatory CAR-T cell product for the treatment of B-cell malignancies, which has demonstrated promising activity in a Phase I clinical trial. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
At the Malaghan Institute, which is a research organization in New Zealand, we’ve developed a third generation CAR-T cell construct, which includes a TLR2 costimulatory domain alongside CD28. And these CAR-T cells are CD19-targeting, so they’re for B-cell malignancies. And what we’ve found through various in vitro assays looking at killing and cytokine production and expansion in vitro, we know that these CAR-T cells display really good killing against target cells and they also secrete less pro-inflammatory cytokines that potentially could cause toxicities in vivo...
At the Malaghan Institute, which is a research organization in New Zealand, we’ve developed a third generation CAR-T cell construct, which includes a TLR2 costimulatory domain alongside CD28. And these CAR-T cells are CD19-targeting, so they’re for B-cell malignancies. And what we’ve found through various in vitro assays looking at killing and cytokine production and expansion in vitro, we know that these CAR-T cells display really good killing against target cells and they also secrete less pro-inflammatory cytokines that potentially could cause toxicities in vivo. And we’ve found that these results are reflected in our Phase I clinical trial in patients. We’ve seen only low levels of CRS, so grade one and two, and no ICANS or neurotoxicity whatsoever in our patients. In our Phase I trial, we’re really happy with the results coming out and we are looking at moving this forward into a Phase II at the moment.
Read more...
